Integrative Training in Oncogenic Signaling
致癌信号综合培训
基本信息
- 批准号:9312769
- 负责人:
- 金额:$ 31.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-08 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
PROJECT SUMMARY/ABSTRACT
This proposal seeks National Cancer Institute (NCI) support for an exciting new Integrative Training in
Oncogenic Signaling (ITOS) Program that has been developed by a select group of cancer scientists affiliated
with the Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC). The ITOS
Program takes place in this active and growing medical center environment with state-of-the-art facilities, a
vibrant NCI-designated cancer center, and an active Office of Postdoctoral Affairs. Led by a Program Director
with an exceptionally strong cancer research background and leadership experience, the ITOS Program will
select and support the placement of trainees in experienced, well-funded, productive laboratories led by the
Program Faculty who reside in an interactive, multi-departmental research environment with extensive
resources. Each trainee will have a primary mentor and one or two secondary mentors with complementary
expertise to ensure distinct and valuable perspectives that will enhance the overall cancer-related research
training experience. The objectives of this training program are to provide proactive mentoring and oversight
and research training in cutting-edge methodology; to develop useful academic and essential career
development skills; to foster collaborative, interdisciplinary interactions with faculty and other trainees; and to
provide exposure to current cancer research discoveries and how these are being translated into novel
approaches to prevention, diagnosis, and treatment of cancer.
Slated to train five postdoctoral trainees each year for five years, this robust training opportunity has seven
programmatic components essential in obtaining the aforementioned objectives. These include the following
components: 1) 33 Program Faculty who share common interests in cancer research and will provide the
essential mentoring for trainees; 2) one to two year experiences in Program Faculty laboratories found within
the vibrant HCC research environment; 3) an ITOS Program Research Club providing an engaging community
forum for the trainees and Program Faculty to discuss work in progress as well as the latest discoveries in
cancer science; 4) shared research resource workshops and tailored training with experts in cutting-edge
biotechnologies; 5) interdisciplinary engagement with trainees in HCC-sponsored thematic research retreats,
symposia, work in progress meetings, and seminars; 6) career development workshops and courses that will
equip trainees for independent success; and 7) opportunities to network nationally at a minimum of two
professional conferences each year. In summary, the ITOS Program will offer distinct experiences and
opportunities only afforded to the selected ITOS Fellows, and the program, led by an outstanding cadre of
Program Faculty, is anticipated to be highly attractive to emerging junior investigators locally and nationally.
项目摘要/摘要
该建议寻求国家癌症研究所(NCI)支持激动人心的新综合培训
由一组癌症科学家制定的致癌信号传导(ITOS)计划
与南卡罗来纳州医科大学(MUSC)的Hollings癌症中心(HCC)一起。 ITOS
计划在这个活跃而不断增长的医疗中心环境中进行,最先进的设施,
充满活力的NCI指定的癌症中心,以及博士后事务的积极办公室。由计划主管领导
ITOS计划将具有异常强大的癌症研究背景和领导经验,将
选择并支持受训者在经验丰富,资金充足,高产的实验室中的位置
居住在互动,多部门研究环境中的计划教师
资源。每个学员将有一个主要导师和一两个次级导师,并具有互补的
专业知识以确保独特而有价值的观点,以增强与癌症相关的整体研究
培训经验。该培训计划的目标是提供积极的指导和监督
和最先进方法论的研究培训;发展有用的学术和基本职业
发展技能;为了促进合作,与教师和其他学员的跨学科互动;然后
提供当前的癌症研究发现,以及如何将其转化为新颖
预防,诊断和治疗癌症的方法。
这个强大的训练机会计划每年培训五名博士后学员,有7个
获得上述目标必不可少的程序组件。这些包括以下
组成部分:1)33计划教师,他们在癌症研究中具有共同利益,并将提供
对学员的基本指导; 2)在计划中发现的一到两年的课程教师实验室经验
充满活力的HCC研究环境; 3)ITOS计划研究俱乐部,提供引人入胜的社区
学员和计划教师的论坛讨论正在进行的工作以及最新发现
癌症科学; 4)共享研究资源研讨会和量身定制的培训
生物技术; 5)跨学科与受训者在HCC赞助的主题研究务虚会中的互动,
专题讨论会,进步会议和研讨会; 6)职业发展研讨会和课程
为学员配备独立成功; 7)至少有两个人在全国建立网络的机会
每年的专业会议。总而言之,ITOS计划将提供不同的体验,并且
仅给选定的ITOS研究员提供的机会,该计划由一个出色的干部领导
计划教师预计将对新兴的初级调查员在本地和全国范围内具有很高的吸引力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Philip H Howe其他文献
Philip H Howe的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Philip H Howe', 18)}}的其他基金
TGFbeta-regulated epithelial-mesenchymal transition (EMT)
TGFβ调节的上皮间质转化(EMT)
- 批准号:
10548115 - 财政年份:2011
- 资助金额:
$ 31.8万 - 项目类别:
TGFbeta-regulated epithelial-mesenchymal transition (EMT)
TGFβ调节的上皮间质转化(EMT)
- 批准号:
10292840 - 财政年份:2011
- 资助金额:
$ 31.8万 - 项目类别:
相似国自然基金
硫化氢抑制采后枸杞乙烯生物合成及其信号转导的机理研究
- 批准号:32360612
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
IFT20通过影响伪足小体组装及其机械力信号转导调控破骨细胞骨吸收的机制研究
- 批准号:32370816
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
NMR研究乳酸化TGIF1调控TGF-β/Smad信号转导通路的分子机制
- 批准号:22374155
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
蛋白酶体介导蛋白质降解、细胞稳态及相关信号转导的机制
- 批准号:32330027
- 批准年份:2023
- 资助金额:209 万元
- 项目类别:重点项目
温度依赖型性别决定龟类物种性腺细胞介导温度信号转导的分子机制
- 批准号:32371570
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
The context-dependent role of Caveolin-1 as a driver of cellular adaptation in Ewing Sarcoma
Caveolin-1 作为尤文肉瘤细胞适应驱动因素的背景依赖性作用
- 批准号:
10662162 - 财政年份:2023
- 资助金额:
$ 31.8万 - 项目类别:
Structure and Function of the SHOC2 Holophosphatase Complex in RAS-driven Cancer
SHOC2 全磷酸酶复合物在 RAS 驱动的癌症中的结构和功能
- 批准号:
10662750 - 财政年份:2023
- 资助金额:
$ 31.8万 - 项目类别:
Understand Non-canonical RAS Signaling in Clonal Hematopoietic Disorders
了解克隆性造血疾病中的非典型 RAS 信号转导
- 批准号:
10571352 - 财政年份:2023
- 资助金额:
$ 31.8万 - 项目类别:
Characterizing and Targeting ERBB2 Mutations in Invasive Lobular Carcinoma
侵袭性小叶癌中 ERBB2 突变的特征和靶向
- 批准号:
10749213 - 财政年份:2023
- 资助金额:
$ 31.8万 - 项目类别:
Dissecting the tumor cell-immune TME axis to identify therapeutically actionable vulnerabilities that potentiate immunotherapy in GBM
剖析肿瘤细胞免疫 TME 轴,以确定可增强 GBM 免疫治疗的治疗上可操作的漏洞
- 批准号:
10743534 - 财政年份:2023
- 资助金额:
$ 31.8万 - 项目类别: